Eun Yang
Stock Analyst at Jefferies
(0.36)
# 4,198
Out of 4,966 analysts
34
Total ratings
26.32%
Success rate
-28.52%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $304.76 | +41.75% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $2.92 | +173.97% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $6.18 | +336.89% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.54 | +179.54% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $51.76 | -36.24% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.95 | +1,335.90% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $20.27 | +33.20% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.94 | +260.82% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.37 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.24 | +671.60% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $3.19 | +470,119.44% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.28 | +1,853.13% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $16.79 | +108.46% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $287.71 | -23.53% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $132.22 | +134.46% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $112.97 | -29.18% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $304.76
Upside: +41.75%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $2.92
Upside: +173.97%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $6.18
Upside: +336.89%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.54
Upside: +179.54%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $51.76
Upside: -36.24%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.95
Upside: +1,335.90%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $20.27
Upside: +33.20%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.94
Upside: +260.82%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.37
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.24
Upside: +671.60%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $3.19
Upside: +470,119.44%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.28
Upside: +1,853.13%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $16.79
Upside: +108.46%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $287.71
Upside: -23.53%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $132.22
Upside: +134.46%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $112.97
Upside: -29.18%